• Novartis

    Novartis announced a 5 percent decrease in net income, to $2.5 million, for the second quarter of 2013 compared to the same quarter last year. Net sales rose slightly to $14.5 billion. The company noted the negative impact of the weakening yen on operating income. It also mentioned increased competition from generic pharmaceuticals and patent expirations.